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Abstract
Objectives
To characterize the host response to dendritic cell-based immunotherapy and subsequent
combined antiretroviral therapy (cART) interruption in HIV-1-infected individuals at the
plasma protein level.
Design
An autologous dendritic cell (DC) therapeutic vaccine was administered to HIV-infected indi-
viduals, stable on cART. The effect of vaccination was evaluated at the plasma protein level
during the period preceding cART interruption, during analytical therapy interruption and at
viral reactivation. Healthy controls and post-exposure prophylactically treated healthy indi-
viduals were included as controls.
Methods
Plasma marker (‘analyte’) levels including cytokines, chemokines, growth factors, and hor-
mones were measured in trial participants and control plasma samples using a multiplex
immunoassay. Analyte levels were analysed using principle component analysis, cluster
analysis and limma. Blood neutrophil counts were analysed using linear regression.
Results
Plasma analyte levels of HIV-infected individuals are markedly different from those of
healthy controls and HIV-negative individuals receiving post-exposure prophylaxis. Viral
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reactivation following cART interruption also affects multiple analytes, but cART interruption
itself only has only a minor effect. We find that Thyroxine-Binding Globulin (TBG) levels
and late-stage neutrophil numbers correlate with the time off cART after DC vaccination.
Furthermore, analysis shows that cART alters several regulators of blood glucose levels,
including C-peptide, chromogranin-A and leptin. HIV reactivation is associated with the
upregulation of CXCR3 ligands.
Conclusions
Chronic HIV infection leads to a change in multiple plasma analyte levels, as does virus
reactivation after cART interruption. Furthermore, we find evidence for the involvement of
TBG and neutrophils in the response to DC-vaccination in the setting of HIV-infection.
Introduction
Chronic HIV infection is characterized by profound changes in immune function that, if left
untreated, will result in AIDS. A gradual decline of CD4 T cells is a hallmark of untreated HIV
infection, but other immune cells including CD8 T cells and B cells also have altered numbers
and turnover dynamics [1,2]. At the functional level, a pathognomonic feature of HIV infec-
tion is generalized immune activation [3–5]. While combined antiretroviral treatment (cART)
curbs viral replication and thereby reverses CD4 T cell decline, it does not completely restore
immune function [2]. Indeed, it has recently been reported that cART is not distributed evenly
throughout the body, resulting into low-level virus replication occurring in specific anatomical
niches, such as lymph nodes and gut [6]. Alternatives to cART are therefore needed. Immune
intervention strategies such as therapeutic vaccination could offer an attractive alternative for
cART: with fewer side effects, no need for lifelong strict therapy adherence, better availability
and cost reduction. Many therapeutic HIV vaccination studies have been conducted, some
with encouraging results [7,8] as demonstrated by a reduction of plasma viral load (lower set
point) or a prolonged time of therapy interruption [9]. In these therapeutic vaccination stud-
ies, a range of clinical and laboratory parameters was assessed to monitor vaccine safety, but
no classical correlates of vaccine efficacy could be identified to guide next generation vaccine
trials. Therefore, other readouts have been used to assess the effect of vaccination, including a
decrease of the viral set point after therapy [8].
In the phase I/IIa clinical trial “DC-TRN”, we vaccinated HIV-infected individuals with
autologous dendritic cells expressing HIV regulatory proteins [10] prior to analytical cART
interruption. DC-TRN was a non-randomized, non-blinded trial evaluating the safety and
immunogenicity of DC-based immunotherapy in cART-treated HIV-infected patients. The
clinical protocol of the trial has been detailed in Allard et al [10]. Briefly, 17 HIV-1 subtype B
infected males, stable on cART, were vaccinated both subcutaneously and intra-dermally on
four occasions with four-week intervals (Fig 1, for patient characteristics, please see Table 1).
The vaccine consisted of autologous mature DCs electroporated with sig-Tat-DC-Lamp, sig-
Rev-DC-Lamp or sig-Nef-DC-Lamp mRNA [11]. Two weeks after the last vaccination,
patients were submitted to analytical treatment interruption (ATI). CD4 or CD8 T-cell
responses as measured by ex vivo stimulation assays were used to assess the vaccine responses
[10]. Additionally, the time off cART, which ranged from 3 months to 7 years, was used as a
vaccine response variable as this approaches the ‘functional cure’ that immunotherapy aims to
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provide. Transcriptome analysis of peripheral blood mononuclear cells (PBMC) obtained
from the DC-TRN trial participants revealed a profound vaccine induced, long lasting, tran-
scriptome shift enriched for genes related to cellular immunity and general immune activation
[12]. These results further corroborate the fact that DC-vaccination boosts the host response
in HIV-infected individuals. In circulating PBMCs, however, transcriptome changes that were
associated with vaccination success could not be identified.
Plasma concentrations of analytes, including cytokines, chemokines, and hormones, reflect
regulatory processes of inflammatory events and may also be affected by the host response to
HIV infection. Previous studies have utilized plasma analyte levels to study inflammatory pro-
cesses in a variety of infectious diseases, including dengue [13], hepatitis B [14] and acute and
chronic HIV infection [5,15–17]. The advantage of measuring analytes is that they represent
the primary regulatory mediators in the blood of patients and are therefore well suited for
investigating immune-regulatory changes in response to HIV infection and DC-vaccination.
In the present study, we investigate the effect of therapeutic DC-vaccination in the setting
of chronic HIV-1 infection [10,12] on plasma analyte levels. We use ‘time off cART’ as a surro-
gate marker of vaccine success, and relate it to changes in plasma analyte levels. The protein
analyte profiling data demonstrate induction of cellular immunity and the upregulation neu-
trophil-related factors in HIV infection and DC vaccination. Therefore, we also investigate
neutrophil counts and we show that they also associate with time off cART. Furthermore, we
study plasma analyte level changes induced by HIV infection on cART, and the effect of cART
treatment by itself and viral rebound on these analyte levels.
Materials and methods
Patients and controls
Seventeen patients chronically infected with HIV-1 subtype B on stable cART and with unde-
tectable plasma viral load (PVL) were recruited in the DC-TRN trial [10] (Netherlands trial
registry NTR2198; Table 1). All patients were Caucasian men who have sex with men (MSM).
Patients co-infected with HBV, HCV were excluded from the study. Before inclusion, all
patients provided written informed consent, in accordance with the regulations of the institu-
tional ethical committees at the University Hospital Brussels and Erasmus Medical Centre
Rotterdam (VUB 05–001 and MEC 2005–227). As controls, peripheral blood samples of ten
healthy adults (anonymized laboratory personnel) from the same region and of the same age
range were included in the study. In addition, three healthy individuals receiving cART in
the context of post-exposure prophylaxis (PEP) treatment administered after a possible trans-
mission event, were collected. They were all treated with Combivir (3TC, AZT) and Kaletra
(LPV/r). They were in the same age range as controls and vaccinees. No CD4 counts have been
Fig 1. Study setup. Eligible HIV+ individuals were recruited into the study. They were given 4 autologous dendritic
cell vaccinations at 4 week intervals, followed by analytical treatment interruption (ATI). Plasma analytes were
measured before vaccination (‘PreVac’), after the third vaccination (Vac#3), just after commencing ATI, and when
plasma virus loads become detectable again (ATI+PVL). The bar indicates the phases around the sampling points that
were used for summarizing the neutrophil counts (N1-5).
https://doi.org/10.1371/journal.pone.0192278.g001
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determined and no seroconversion has been documented after PEP. Plasma samples were iso-
lated from EDTA tubes (Becton Dickinson, Breda, The Netherlands) by centrifugation and
processed the same day for storage at -80˚C.
Analyte levels measurements and processing
Plasma samples were sent frozen to Myriad RBM and multiplex immunoassay panel Human
DiscoveryMAP1 250+ v2.0 (Myriad RBM, Texas, USA) was used at the Clinical Laboratory
Improvement Amendments (CLIA)-certified laboratory for measuring the levels of multiple
analytes in plasma of trial subjects and controls. The multiplex assay comprised measurement
of cytokines, chemokines, growth factors, hormones, metabolic markers, angiogenesis mark-
ers, tissue remodelling proteins, acute phase reactants, cancer markers, kidney damage mark-
ers, CNS biomarkers and other circulating proteins. In total, 243 analytes were quantified (see
supporting information) using duplicate 8-point standard curves and 3 control samples at low,
medium and high concentrations run in duplicate for each assay. Analytes with similar con-
centrations were combined into specific multiplexes and measured simultaneously. Concen-
trations were interpolated from four or five parameter logistic curves. Analytes showing no
changes in any sample were excluded, leaving 207 analytes for analysis (S1 Fig, S1 Table). Plots
for all analytes are provided in the supplementary material as a resource accompanying this
paper (S1 File).
Data processing
Analyte analysis was performed in R, an environment for statistical computing [18]. All ana-
lyte concentrations were log-transformed before analysis. Initial analysis indicated an effect of
the clinical center, separating the Belgian and Dutch samples. This center (batch) effect was
removed with ComBat [19]. Differential analyte expression analysis was performed using
limma [20]. Heatmaps of analyte expression were constructed by hierarchical clustering using
correlation distance and Ward’s linkage [21]. For cluster analysis, several sample selections
from the primary dataset were studied: a dataset including, respectively, all samples; samples
from trial participants only; and a trial participants-only set from which the intra-individual
analyte patterns have been removed with the removeBatchEffect function from the limma
package [20].
Statistical analysis
Statistically significant analyte level differences between groups of patients and at the indicated
time points (i.e., before, during and after DC vaccination and at treatment interruption) were
performed using limma [20]. Analytes were considered differentially expressed whenever a
false discovery rate (FDR) of< 0.05 and at least a 1.5-fold up- or down-regulation between
groups was observed.
A Cox proportional hazards model was used to assess whether any analytes are associated
with the long-term outcome of DC vaccination. The outcome variable was ‘time off cART’ and
analyte measurements at PreVac (week 0; Fig 1), ATI (week 15) and ATI+PVL (week 22) were
time dependent predictors. Note that because of the correlation between these three time
dependent predictors, we tested the combined association of the predictors with time off
cART by performing a Chi-square test to compare the prediction models with and without the
analyte measurements at the three time points. The analyte measurements at Vac#3 were
excluded from the analysis, as no plasma sample was available for six patients. In addition, the
analysis was restricted to 15 of the 17 patients who had analytes measured at these three time
points. We conducted multiple imputation for missing analyte measures under the null
Protein profiles of HIV-DC immunotherapy
PLOS ONE | https://doi.org/10.1371/journal.pone.0192278 February 1, 2018 6 / 17
hypothesis [22] for 20 analytes (11 with less than 5% missing, 6 with 5–10% missing and 3 with
10–13.3% missing, S2 Table) and used ComBat to remove batch effects.
Neutrophil count analysis
Blood absolute neutrophil counts (ANC) were routinely performed at multiple time points for
all patients. To obtain a robust estimate of ANC, the counts were stratified into the five rele-
vant study phases of the trial (N1 –N5, Fig 1) and summarized using the median value. Regres-
sion analysis was performed to assess the association between ANC and time off cART.
Removal of any single sample did not affect the outcome of this analysis, nor did the addition
of single factor covariates including ANC at other time points and origin of patients.
Results
HIV infection but not cART treatment affects global analyte levels
Blood plasma was collected from HIV patients at various time points before, during and after
DC immunotherapy (see Fig 1), as well as from healthy controls (HC) and individuals treated
with cART as post-exposure prophylaxis (PEP). Samples were annotated by trial stage, i.e.,
cART-treated HIV-infected individuals with pVL below the lower limit of detection (<50 cop-
ies/ml) sampled before vaccination (‘PreVac’); one week after the third administration of the
DC-vaccine (while patients are still under cART, ‘Vac.3’); one week after analytical treatment
interruption (ATI); and 10 weeks after ATI, once patients had become viraemic (‘ATI.PVL’,
Fig 1). Following ATI, the median time to viral rebound was 3.1 weeks and pVL increased to
>3 log10 copies/ml after a median of 4.7 weeks [10]. For DC-TRN trial participant details, see
Table 1.
To obtain a bird’s eye view of the analyte expression data, we perform principle component
analysis. The first principal component identifies HIV infection as the main source of variabil-
ity, separating the samples into two groups representing respectively HC/PEP and HIV
patients (Fig 2). This analysis suggests small effects, if any, of cART on the analyte levels, since
the samples from the HIV-infected study participants do not aggregate by cART treatment,
and since the PEP samples are located firmly in the HC group. PCA indicates that PreVac
tends to be more similar to HC than samples from the other phases of the trial. Samples from
the Vaccination and ATI groups are intermingled, whereas samples taken when the viral load
rebounded tend to be located on the left of PC1. Taken together, this analysis indicates that
there is a difference in analyte expression between HIV-positive and HIV-negative individuals,
regardless of vaccination, therapy or virus reactivation.
Samples cluster by trial stage after correcting for intra-individual effects on
analyte profiles
In order to evaluate the effect, if any, of the DC-TRN trial stages on the analyte expression pat-
tern, we applied cluster analysis to the HIV+ (i.e., DCTRN trial) samples only [21,23]. A con-
sistent clustering of samples originating from the same patient is noticeable (S2a Fig). In the
initial cluster analysis, no clustering by vaccination or viraemic status (S3 Fig) is observed.
However, upon mathematical correction for the individual specific effect on the analyte pro-
file, cluster analysis reveals a clustering that relates to the phase and status in the vaccination
trial (Fig 3). Clusters A, B, and C contain primarily PreVac samples, samples taken after vacci-
nation or after ATI, and samples collected during viral rebound, respectively. The data reveal
little effect of cART interruption as we see no segregation based on cART status (see Table 1).
Protein profiles of HIV-DC immunotherapy
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In summary, this analysis shows that virus reactivation induces the largest change in analyte
expression within the DC-TRN trial participants.
Markers of long-term outcome
Previous analyses of data obtained from this trial, including B and T cell responses and PBMC
transcriptome analysis [10,12,24], did not reveal a biomarker for the time off cART. Time off
cART may not be the optimal correlate of protection as therapy can be biased by physician or
patient appraisal. However, some study participants control the virus and maintain CD4+ T
cell numbers for a considerable period of time without cART. Therefore, we use “time off
cART” as an outcome in the identification of biomarkers among the plasma analytes. To this
end (see Table 1), we used a Cox proportional hazards model with time off cART as outcome
variable and analyte measurements at PreVac (week 0; Fig 1), ATI (week 15 from the first vac-
cination) and ATI+PVL (week 22) as predictor variables. A longer time off cART is signifi-
cantly associated with Thyroxine-Binding Globulin (TBG; P = 2.66x10-4 and when corrected
for multiple testing P = 0.0423, see S3 Table). To better understand the relationship between
TBG and long-term outcome, we examined the levels of TBG as a function of time off cART
Fig 2. PCA of all samples. Missing values were removed by either excluding the analytes that contain missing values,
or patients that have missing values.
https://doi.org/10.1371/journal.pone.0192278.g002
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(S4 Fig). Although the levels of TBG in the DCTRN trial participants are in the same range as
observed in healthy controls, we notice that participants that have a long time off cART period
tend to exhibit a different change in TBG levels that the other participants. In participants that
resumed cART early, TBG levels are highest at virus reactivation (i.e., study week 22); in par-
ticipants that remain off cART for a longer time, TBG levels tend to be highest at the ATI stage
(i.e., study week 15). A further 30 analytes have uncorrected P< 0.05 and are considered to be
worth further study (S3 Table).
Fig 3. Heatmap of analyte measurements in DC-TRN trial participants. All measurements were corrected for patient effect. Three sample clusters
are observed, which have been labelled A-C. The DCTRN trial stage at which the sample was taken in indicated by the left-most colour bar.
https://doi.org/10.1371/journal.pone.0192278.g003
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Differential expression of HIV-specific factors in patients stable on cART
In addition to identifying biomarkers associated with a longer time off cART, we also examine
associations between changes in analyte concentration during the trial and other independent
clinical variables. By statistical modelling using limma, we are able to identify analytes that
specifically and significantly associate with each of the trial stages. The largest number of sig-
nificant differentially expressed analytes is found for the HIV-treated—HC difference. Addi-
tionally, we identify analytes that were differentially expressed as a result of cART treatment
and virus reactivation (Fig 4).
HIV infection is associated with an increase in IFNγ levels, which is a marker of an
increased cellular immune response. In addition, HIV infection is associated with a decrease
in S100 protein family members S100A12 (EN-RAGE), S100A4, and a small decrease in
S100B. RAGE, which is a receptor for S100B and is expressed on neutrophils [25] is up-regu-
lated. Overall, more analytes are down-regulated than are up-regulated. The differences
between HIV-on-cART individuals and healthy controls can mostly be attributed to HIV-
induced changes, because the effect of cART in HIV-negative individuals affects other analytes
(Fig 4), although these results should be interpreted with caution given the small number of
PEP subjects.
Fig 4. Differential expression analysis of analytes. The names of analytes that are differentially expressed are
depicted in circles for HIV infection stable on treatment vs healthy controls (‘HIV+’), cART treatment being treated
HIV negative vs health control (‘treatment’) and virus reactivation as seen after stop cART, i.e., ATI.PVL—ATI (called
‘reactivation’). Up- and down-regulated analytes are depicted in red or green, respectively. ITAC is up-regulated
during virus reactivation and down-regulated in during HIV infection.
https://doi.org/10.1371/journal.pone.0192278.g004
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cART up-regulates markers of insulin resistance
Enrolment of both HIV-infected and non-HIV-infected individuals receiving cART allows the
examination of the effect of cART independent of HIV infection. cART is associated with an
increase in both the T-cell associated chemotactic cytokines MIP1β (CCL4) and MIP3β
(CCL19) (Fig 4). CgG (Chromogranin-A) promotes the secretion of insulin from beta-islets
and is also increased in samples taken under cART-treatment. Furthermore, levels of C-pep-
tide, a cleavage product of insulin, and leptin were increased in cART-treated individuals. This
effect on blood glucose regulation that is indicative of HIV metabolic syndrome that may lead
to diabetes mellitus and cardio-vascular diseases [26]. cART treatment is also associated with
an increase in MIP1β that is produced by CD8+ T cells and has strong anti-HIV activity [27].
Active HIV replication induces CXCR3 ligands
Viral rebound as a result of productive HIV replication after cART interruption induced sev-
eral changes in analyte levels. We observe an increase in MCP-2 (CCL8) (Fig 4), which is a
potent HIV inhibitor by virtue of its strong affinity for the HIV co-receptor CCR5 [28]. MIP3β
(CCL19), which attracts DCs, B and T cells towards lymph nodes via binding of its receptor
CCR7, is up-regulated. Virus replication is also associated with an increase in MIG (CXCL9),
IP-10 (CXCL10), and I-TAC (CXCL11). These chemokines are all induced by IFNγ, and are
all ligands for chemokine receptor CXCR3, which mediates T-cell trafficking to lymphoid and
mucosal tissues. Both IP-10 and I-TAC are known to be up-regulated by HIV replication
[29,30]. Furthermore, there is evidence for a role of IP-10 and CXCR3 in the integration of
HIV in resting CD4+ T cells that promotes virus persistence within the host [31]. Our results
show that MIG expression is higher in samples taken during active virus replication.
Late-stage granulocyte counts associate with duration of cART-free period
after DC vaccination
No analytes are significantly differentially expressed in plasma upon DC vaccination. How-
ever, five analytes, MPO, RANTES (CCL5), GRO-α (CXCL1), NSE, and Matrix Metalloprotei-
ninase (MMP)-10, of which three are associated with granulocytes, display a borderline
increase (FDR < 0.1) upon vaccination. This prompted us to evaluate the association between
time off cART and the number of neutrophils in circulation by analysing the absolute neutro-
phil counts (ANC) of our subjects during the trial.
To perform a global trend analysis of the variable ANC, counts are summarized by trial
period using median averaging. By evaluating the neutrophil counts at several study phases,
we can attribute the change in circulating neutrophil levels to different factors. By fitting a
regression model of neutrophil counts during the various phases of the trial (Fig 1, N1-N5), we
observe that late-stage neutrophil counts associate best with time off cART (Fig 5). The results
support the involvement of neutrophils in the response to HIV and to DC vaccination in a
chronic HIV-setting.
Discussion
In this study, we profile the response of chronically HIV-infected individuals to DC-vaccine-
mediated immunotherapy with a high-throughput assay quantifying over 200 analytes in
peripheral blood. With this approach, we are able to directly monitor regulatory molecules
that circulate in the periphery, irrespective of the tissue source, rather than monitoring host
response mediators such as mRNA expressed in circulating lymphoid cells. Using both the
DC-vaccinated DC-TRN study subjects as well as healthy controls and post-exposure
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prophylactically treated individuals (PEP), we are able to detect changes in regulatory mole-
cules in response to HIV-infection, DC vaccination, cART treatment and virus reactivation
during cART interruption. Plasma analyte profiling revealed DC-vaccination and viral
rebound associated responses characterized by immune activation and involvement of
neutrophils.
Overall analyte profile changes, as visualized by principal component analysis, demon-
strated that the profiles from healthy controls (HC) and HIV negative individuals on cART
(PEP) clearly differ from HIV-infected individuals, even when virus cannot be detected in
plasma. Interestingly, only upon adjustment for individual (study participant) specific analyte
expression levels, a superimposed pattern discriminating pre-vac, early post-vac and late post-
vac analyte profiles could be identified by PCA (S2B Fig) and cluster analysis (Fig 3). Viral
rebound upon ATI, but not cART interruption itself, results in significant analyte profile
changes. Previously, PBMC samples collected from the same study participants were subjected
to mRNA profiling [12]. Principle component analysis of the resulting blood transcriptome
profiles revealed a similar marked difference between healthy individuals and chronically HIV
infected individuals. Therapeutic vaccination however had a dominant effect at the mRNA
level. In addition, the DC-vaccination induced transcriptome shift persisted after ATI. Unlike
the analyte profiling results presented here, the major transcriptome shift induced by DC-vac-
cination was not affected by the subsequent viral rebound. This shows that analyte- and
mRNA profiling provide different and complementary information on the host response.
Among the analytes that are differentially expressed in response to HIV infection, several
members of the S100 protein family are down-regulated, including EN-RAGE (S100A12),
S100A4 and S100B. The S100 protein family consists of 24 members that have a wide variety of
functions, including growth, development, inflammation and DAMPs. EN-RAGE is constitu-
tively expressed in neutrophils and its expression causes grow arrest in epithelial cells. S100A4
and S100B are both known to interact with epidermal growth factor. The down-regulation of
these three proteins suggests that epithelial growth is promoted, both through a release of epi-
thelial cell growth factor by a decrease in EN-RAGE, and reduced sequestering of epithelial
growth factor by down regulation of S100B and S100A4 [25]. Our results indicate that the role
of S100 family proteins in HIV pathogenesis warrants further investigation.
Fig 5. Neutrophil counts over the course of the trial. All data available for all patients is shown. The DC-TRN trail phases are indicated in Fig 1. The
regression lines are annotated with significance levels and R-squared values.
https://doi.org/10.1371/journal.pone.0192278.g005
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Study stage-associated differential analyte expression analysis identified the differential
expression of analytes involved in blood sugar regulation, including up-regulation of C-pep-
tide, CaG and leptin during cART therapy, independent of HIV infection. Although this com-
parison is based on three versus ten individuals and should therefore be interpreted with
caution, up-regulation of these analytes is consistent with earlier findings that cART induces
insulin resistance. In fact, insulin resistance is one of the main complications of prolonged
cART therapy, especially in HIV-positive individuals over the age of 50 [32]. Both these find-
ings illustrate the added value of plasma analyte profiling in antiviral strategy evaluation stud-
ies. Since time off cART ranged widely (28–352 weeks), application of techniques such as mass
spectrometry enabling the quantification of a much larger set of plasma analytes may result in
the identification of additional biomarkers of favourable host responses to therapeutic vaccina-
tion, especially when applied in more extended follow-up studies.
Although this phase I/IIa study is not designed for biomarker analysis, we were nevertheless
able to identify the plasma protein thyroxine-binding globulin as a potential biomarker of the
efficacy of DC vaccination in a chronic HIV setting. TBG associates with a longer period off
therapy; it appears that this is primarily due to a difference in how DCTRN trial participants
react to virus reactivation. Most participants that remain off therapy for a prolonged period of
time have a down-regulation of TBG following virus reactivation, whereas others have an up-
regulation. TBG is a regulator of that, along with transthyretin and serum albumin, is responsi-
ble for carrying the thyroid hormones (thyroxine (T4) and 3,5,3’-triiodothyronine (T3)) in the
bloodstream. A change in TBG levels therefore leads to a shift in T4 or T3, which suggests that
patients that remain off therapy for a prolonged period of time have a different metabolic
response to reactivation of virus. Since TBG is considered a marker for multiple metabolic and
oncogenic abnormalities and thought to have a minor role in HIV [33], further study is needed
to establish its use adand relevance. Several other markers that do not reach statistical signifi-
cance after multiple testing correction are considered to be worth further study also (S3
Table). Markers that stand out include IL8, ENA78 and other neutrophil-related cytokines.
Furthermore, markers of metabolic regulation are also related to time off cART, which could
reflect a rebound in metabolic status due to the prolonged absence of cART treatment.
A considerable number of analytes that are differentially expressed at various stages of the
trial are related to neutrophil regulation. This prompted us to enumerate the number of circu-
lating neutrophils in our trial. Despite a considerable variation in neutrophil counts, neutro-
phil numbers correlate positively with a longer time off cART after DC vaccination. Our
analysis does not indicate a causal relationship between higher ANC and a longer period off
cART, since the ANC collected during the last phase of the trial correlated best with time off
cART. However, in our study, multiple analytes attracting neutrophils are induced by DC-vac-
cination, suggesting that the neutrophils are indeed specifically induced. Additionally, TBG,
which we found to be related to time off cART, is cleaved by elastin, a protein that is produced
by neutrophils in response to inflammation. This leads to a localized release of T4 that medi-
ates more energy expenditure around sites of inflammation [34]. The decrease of TBG at late
timepoints could therefore be related to the increase of inflammation and neutrophils that we
observe. However, there is no significant difference in inflammatory cytokine expression
between early and late therapy resumers, suggesting that any differences in inflammation are
small.
Omics profiling approaches support vaccine response monitoring [35,36], especially in dif-
ficult vaccine evaluation settings like therapeutic vaccination of a chronic infection [12]. These
high-resolution approaches may reveal host response differences that are easily missed when
solely applying traditional immunological and virological tools, in particular when these
responses are affected by patient-specific factors. We show that combining multiple
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approaches provides different perspectives on the same process; for instance, the role of neu-
trophils has not been noticed before in earlier transcriptome profiling studies since PBMCs
(i.e., blood cell fraction devoid of neutrophils) were analysed [12]. Combining all of these
with integrated systems biology analysis approaches supports the identification of host corre-
lates of sustained viral suppression and the identification of host response biomarkers to guide
a booster vaccination scheme for therapeutic vaccines.
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